Display options
Share it on

Antibiotics (Basel). 2021 Dec 19;10(12). doi: 10.3390/antibiotics10121554.

Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study.

Antibiotics (Basel, Switzerland)

Daniele Roberto Giacobbe, Michele Mirabella, Matteo Rinaldi, Angela Raffaella Losito, Francesca Raffaelli, Filippo Del Puente, Carolina Saffioti, Malgorzata Mikulska, Maddalena Giannella, Pierluigi Viale, Mario Tumbarello, Matteo Bassetti, On Behalf Of Sita Giovani Young Investigators Group Of The Società Italiana Terapia Antinfettiva And

Affiliations

  1. Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
  2. Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
  3. Operative Unit of Infectious Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  4. Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
  5. Department of Infectious Diseases, Galliera Hospital, 16128 Genoa, Italy.
  6. Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
  7. Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

PMID: 34943767 DOI: 10.3390/antibiotics10121554

Abstract

Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients receiving intravenous colistin were included in the analyses. Inadequate colistin dosages were administered in 27% of cases (50/187). In multivariable analysis, AKI (dummy variable with KDIGO stage 0 as a reference, odds ratio (OR) 3.98 with 95% confidence interval (CI) 1.48-10.74 for stage 1, OR 4.44 with 95% CI 1.17-16.93 for stage 2, OR 9.41 with 95% CI 1.59-55.70 for stage 3; overall

Keywords: acute kidney injury; antimicrobial stewardship; colistin; dosage; polymyxin

Publication Types